肿瘤细胞治疗研究
英文原题：CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia.
急性髓系白血病（AML）的特征是未成熟髓系细胞在骨髓和外周血中积聚。
急性髓系白血病（AML）以未成熟髓系细胞在骨髓和外周血中蓄积为特征。近半数 AML 患者接受标准诱导治疗后复发，亟需新的治疗方式。迄今，嵌合抗原受体（CAR）T 疗法因疗效和安全性不足，尚未成功用于 AML。事实上，最受关注的靶抗原为 CD33 或 CD123 等干细胞标志物。本研究证明，成熟 B 细胞标志物 CD37 在 AML 样本中表达，其表达与 2017 年欧洲白血病网（ELN）风险分层相关。研究将抗淋巴瘤 CD37CAR 改用于治疗 AML，发现 CD37CAR T 细胞可特异性杀伤 AML 细胞、分泌促炎细胞因子，并在体内控制癌症进展。重要的是，CD37CAR T 细胞不会对造血干细胞造成毒性。因此，CD37 是一种有前景且安全的 AML CAR-T 靶点。
Acute myeloid leukemia (AML) is characterized by the accumulation of immature myeloid cells in the bone marrow and the peripheral blood. Nearly half of the AML patients relapse after standard induction therapy, and new forms of therapy are urgently needed. Chimeric antigen receptor (CAR) T therapy has so far not been successful in AML due to lack of efficacy and safety. Indeed, the most attractive antigen targets are stem cell markers such as CD33 or CD123. We demonstrate that CD37, a mature B cell marker, is expressed in AML samples, and its presence correlates with the European LeukemiaNet (ELN) 2017 risk stratification. We repurpose the anti-lymphoma CD37CAR for the treatment of AML and show that CD37CAR T cells specifically kill AML cells, secrete proinflammatory cytokines, and control cancer progression in vivo. Importantly, CD37CAR T cells display no toxicity toward hematopoietic stem cells. Thus, CD37 is a promising and safe CAR T cell AML target.
MEMBER ACCOUNT
登录成功会直接打开下一页。
